Use of antenatal corticosteroids prior to preterm birth in four South East Asian countries within the SEA-ORCHID project by Porjai Pattanittum et al.
BioMed CentralBMC Pregnancy and Childbirth
ssOpen AcceResearch article
Use of antenatal corticosteroids prior to preterm birth in four 
South East Asian countries within the SEA-ORCHID project
Porjai Pattanittum1, Melissa R Ewens2, Malinee Laopaiboon1, 
Pisake Lumbiganon3, Steven J McDonald4, Caroline A Crowther*2 and The 
SEA-ORCHID Study Group
Address: 1Department of Biostatistics and Demography, Khon Kaen University, Khon Kaen 40002, Thailand, 2Discipline of Obstetrics and 
Gynaecology, University of Adelaide, SA 5006, Australia, 3Department of Obstetrics and Gynaecology, Khon Kaen University, Khon Kaen 40002, 
Thailand and 4Australasian Cochrane Centre, Monash University, Melbourne, VIC 3168, Australia
Email: Porjai Pattanittum - pporja@kku.ac.th; Melissa R Ewens - melissa.ewens@adelaide.edu.au; Malinee Laopaiboon - malinee@kku.ac.th; 
Pisake Lumbiganon - pisake@kku.ac.th; Steven J McDonald - steve.mcdonald@med.monash.edu.au; 
Caroline A Crowther* - caroline.crowther@adelaide.edu.au; The SEA-ORCHID Study Group - caroline.crowther@adelaide.edu.au
* Corresponding author    
Abstract
Background: There is strong evidence supporting the use of antenatal corticosteroids in women at risk of preterm
birth to promote fetal lung maturation and reduce neonatal mortality and morbidity. This audit aimed to assess the use
of antenatal corticosteroids prior to preterm birth in the nine hospitals in four South East Asian countries participating
in the South East Asia Optimising Reproductive Health in Developing Countries (SEA-ORCHID) Project.
Method: We reviewed the medical records of 9550 women (9665 infants including 111 twins and two triplets) admitted
to the labour wards of nine hospitals in four South East Asian countries during 2005. For women who gave birth before
34 weeks gestation we collected information on women's demographic and pregnancy background, the type, dose and
use of corticosteroids, and key birth and infant outcomes.
Results: Administration of antenatal corticosteroids to women who gave birth before 34 weeks gestation varied widely
between countries (9% to 73%) and also between hospitals within countries (0% to 86%). Antenatal corticosteroids were
most commonly given when women were between 28 and 34 weeks gestation (80%). Overall 6% of women received
repeat doses of corticosteroids. Dexamethasone was the only type of antenatal corticosteroid used.
Women receiving antenatal corticosteroids compared with those not given antenatal corticosteroids were less likely to
have had a previous pregnancy and to be booked for birth at the hospital and almost three times as likely to have a
current multiple pregnancy. Exposed women were less likely to be induced and almost twice as likely to have a caesarean
section, a primary postpartum haemorrhage and postpartum pyrexia.
Infants exposed to antenatal corticosteroids compared with infants not exposed were less likely to die. Live born
exposed infants were less likely to have Apgar scores of < 7 at five minutes and less likely to have any lung disease.
Conclusion: In this survey the use of antenatal corticosteroids prior to preterm birth varied between countries and
hospitals. Evaluation of the enablers and barriers to the uptake of this effective antenatal intervention at individual
hospitals is needed.
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Infants born preterm are at high risk of neonatal lung dis-
ease and associated complications [1]. Respiratory distress
syndrome (RDS), a consequence of immature lung devel-
opment, is the primary cause of early neonatal mortality
[2] and contributes to significant immediate [1] and long-
term morbidity in survivors [3]. Antenatal corticosteroid
treatment for women at risk of very preterm birth before
34 weeks gestation is one of the most effective treatments
for the prevention of RDS, reducing neonatal mortality
and morbidity [4]. This is of importance for developing
countries where resources are scarce and it is often diffi-
cult to provide expensive treatments such as neonatal
care.
Although evidence of benefit for the use of antenatal cor-
ticosteroids has been available for many years [5,6], wide-
spread adoption of this treatment into routine clinical
practice was significantly delayed and implementation of
their use remained suboptimal in developed countries for
many years [7]. There is limited information as to how
well this practice has been implemented in developing
countries.
Objectives of this review
The aim of this audit was therefore to assess the use of
antenatal corticosteroids for women who gave birth at less
than 34 weeks gestation in the nine hospitals across four
South East Asian countries within the South East Asia
Optimising Reproductive Health in Developing Countries
(SEA-ORCHID) Project [8]. Information was collated on
which women received corticosteroids, their sociodemo-
graphics and obstetric history, the type, amount and rea-




Nine hospitals participating in the SEA-ORCHID project
in four South East Asian countries namely Indonesia,
Malaysia, the Philippines and Thailand were audited [9].
Seven of the nine hospitals were tertiary (university and
regional) referral institutions with regional referrals of
women with a high risk pregnancy and two hospitals were
provincial or district institutions. Delivery care models
included obstetric specialists or a multidisciplinary
approach with midwives (including nurses with mid-
wifery qualifications). In all hospitals obstetric specialists
and caesarean section facilities were available and doctors
and/or midwives (including nurses with midwifery quali-
fications) conducted normal vaginal births.
The SEA-ORCHID project settings and methods have
been described elsewhere [8]. The study was approved as
an audit by the local ethics committee of each hospital
and the administering institution in Australia. Individual
patient consent was not therefore sought.
Procedure
Previously, as part of the SEA-ORCHID baseline data col-
lection we completed a prospective audit of the medical
records of 9550 women (9665 infants including 111
twins and two triplets) admitted to the labour wards at the
nine participating SEA-ORCHID hospitals during 2005.
At five of the participating hospitals medical records were
audited on a consecutive basis until a sample of 1000 was
reached. To reduce the risk of bias the four largest partici-
pating hospitals randomly sampled medical records using
various ratios to ensure a sample of 1000 was reached over
the three month data collection period.
For this current audit, staff at each hospital were trained to
use pre-established data extraction forms to prospectively
audit the medical records of the 290 women who gave
birth at < 34 weeks regardless of whether they were given
antenatal corticosteroids or not (Table 1). Data from each
country was sent to Khon Kaen University by post where
it was manually entered into a Microsoft Access 2003
database. The database minimised transcription errors by
performing validation checks to detect discrepancies and
missing data.
Demographic information collected about these women
included maternal age, any previous birth ≥ 22 weeks, ges-
tational age at time of last corticosteroid injection, if
given, whether the pregnancy was singleton or twins,
whether they received public or private care, whether they
were booked for birth at the hospital and the main reason
they were considered at risk of preterm birth (Table 2).
Health outcomes for all infants exposed to antenatal cor-
ticosteroids as well as those who were not were collected
including gestational age at birth, birth weight, stillbirth,
death prior to discharge, live born babies discharged alive,
presence of respiratory distress syndrome, severity of any
lung disease, use of oxygen therapy, use and duration of
mechanical ventilation (defined as intermittent positive
pressure ventilation and/or continuous airways pressure),
Apgar scores and length of hospital stay (Table 3).
Maternal health outcomes of all women were collected
including use of induction of labour, mode of birth, pri-
mary or major postpartum haemorrhage and postpartum
pyrexia (Table 4).
Data Analysis
Descriptive statistics assessed the use of antenatal corticos-
teroids across countries and between hospitals within
countries. Difference of means with 95% confidence
interval (CI) was used to compare factors measured inPage 2 of 8
(page number not for citation purposes)
BMC Pregnancy and Childbirth 2008, 8:47 http://www.biomedcentral.com/1471-2393/8/47continuous data, such as maternal age and birth weight,
between the two groups. When the data were skewed, dif-
ference of medians with 95% CI was used. Independent t-
test or Mann-Whitney U test, where appropriate, was used
for significant comparison of the two groups and results
were shown as p-values. Relative risk (95% CI) and Chi-
square tests were used for comparing the factors measured
in categorical data, such as parity and multiple pregnancy
between the two groups. The analysis was done using
STATA software version 8.0 [10].
Ethics
The SEA-ORCHID project was approved by the local eth-
ics committees of each hospital and by the ethics commit-
Table 1: Percentage distribution of women who gave birth at < 34 weeks GA and corticosteroid use
Countries Hospitals Number of women who
gave birth at < 34 weeks
Antenatal corticosteroids given to women
who gave birth at < 34 weeks
n (%) n (%)
Indonesia Overall 90 (4) 8 (9)
Tertiary 69 (7) 6 (9)
District 21 (2) 2 (10)
Malaysia Overall 51 (2) 28 (55)
Tertiary 1 32 (3) 19 (59)
Tertiary 2 19 (2) 9 (47)
The Philippines Overall 48 (2) 7 (15)
Tertiary 1 15 (1) 0 (0)
Tertiary 2 33 (3) 7 (21)
Thailand Overall 101 (3) 74 (73)
Regional 51 (5) 44 (86)
University 25 (3) 15 (60)
Provincial 25 (3) 15 (60)
Figures are numbers with percentages rounded to the nearest whole number in brackets.
Table 2: Characteristics of women receiving/not receiving antenatal corticosteroids with birth 24 to < 34 weeks gestational age
Antenatal corticosteroids
Received Not received Comparative statistic# 95% CI p-value
n = 104 n = 148
Maternal Age* (years) 27.6 (6.8) 28.5 (6.9) -0.85 -2.59; 0.88 0.34
Parity ‡
Previous pregnancies ≥ 22 weeks 47 (45) 86 (58) 0.77 0.60; 0.99 0.04
Gestational age at last injection
< 24 – 27 weeks 20 (19) -
28 – 31 weeks 42 (40) - N/A N/A N/A
32 – < 34 weeks 42 (40) -
Multiple pregnancy
Twins 10 (10) 5 (3) 2.84 1.0; 8.1 0.04
Patient status ‡
Public 98 (94) 144 (98) 0.96 0.91; 1.01 0.12
Booked for birth at hospital ‡ 81 (79) 136 (92) 0.86 0.77; 0.96 0.01
Main reasons for risk of preterm birth 0.01
Preterm labour 42 (40) 36 (24) - -
PPROM 26 (25) 19 (13) - -
Hypertension 18 (17) 18 (12) - -
APH 6 (6) 9 (6) - -
Maternal conditions 4 (4) 6 (4) - -
Multiple pregnancy 2 (2) 2 (1) - -
Fetal concern 1 (1) 8 (5) - -
Other/not recorded 5 (5) 50 (34) - -
Figures are numbers with percentages rounded to the nearest whole number in brackets and with relative risk and 95% confidence intervals as the 
comparative statistic#, or *Mean and standard deviation with mean difference between groups and 95% confidence intervals as the comparative 
statistic#. ‡Outcomes not available for a few womenPage 3 of 8
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institution in Australia.
Results
Corticosteroid administration in South East Asian 
countries (Table 1)
Antenatal corticosteroids were not frequently adminis-
tered to women who gave birth at less than 34 weeks ges-
tation at any of the hospitals audited across the four South
East Asian countries. Of the 290 women who gave birth at
less than 34 weeks gestation presenting to the audited
hospitals, 117 (40%) received antenatal corticosteroids.
Thai and Malaysian hospitals showed the highest usage of
antenatal corticosteroids for women who gave birth
before 34 weeks gestation (73% and 55% respectively).
Less than 10% of women who gave birth preterm at Indo-
nesian hospitals were reported to be given antenatal corti-
costeroids. Hospitals in The Philippines recorded a low
rate of antenatal corticosteroid use with one hospital not
administering corticosteroids to any women who gave
birth preterm.
Table 3: Health outcomes for infants exposed to antenatal corticosteroids versus those not exposed
Antenatal corticosteroids
Exposed Not exposed Comparative statistic# 95% CI p-value
All babies n = 114 n = 152
Gestational age at birth*‡ (weeks.days) 30.4 (2.6) 29.9 (2.7) 0.47 -0.19; 1.13 0.16
Birth weight*‡ (kg) 1.62 (0.65) 1.48 (0.63) 0.14 -0.02; 0.29 0.08
Stillbirth 2 (2) 42 (28) 0.06 0.02; 0.25 0.01
All deaths (stillbirths/deaths prior to discharge) 18 (16) 49 (32) 0.49 0.30; 0.79 0.01
Mode of birth 0.01
normal vaginal 59 (52) 99 (65) 1 -- --
vaginal breech 4 (4) 19 (13) 0.39 0.14; 1.11 0.06
operative vaginal birth 2 (2) 2 (1) 1.65 0.24; 11.45 0.63
caesarean section 49 (43) 32 (21) 1.85 1.28: 2.67 0.01
Live born babies n = 112 n = 111
Live born babies discharged alive 96 (86) 103 (93) 0.92 0.84; 1.0 0.05
Respiratory distress syndrome ‡‡ 59 (60) 54 (57) 1.06 0.83; 1.34 0.64
Severity of lung disease§ 0.01
none 22 (30) 4 (11) 1 -- --
mild 7 (9) 15 (42) -- -- --
moderate 27 (37) 6 (17) -- -- --
severe 18 (24) 11 (30) -- --
Use of oxygen therapy¶ 50 (50) 55 (57) 0.86 0.66; 1.12 0.27
Use of mechanical ventilation¶ 53 (54) 25 (39) 1.38 0.97; 1.98 0.06
Apgar Score < 7 at 1 min † 42 (38) 57 (52) 0.73 0.54; 0.98 0.04
Apgar Score < 7 at 5 min † 15 (14) 34 (31) 0.44 0.25; 0.75 0.01
Figures are numbers with percentages rounded to the nearest whole number in brackets and with relative risk and 95% confidence intervals as the 
comparative statistic#, or *mean and standard deviation with mean difference between groups and 95% confidence intervals as the comparative 
statistic#. §Severity of lung disease is defined as none (no oxygen required), mild (Oxygen < 40% FiO2), moderate (FiO2 40–79%), severe (FiO2 80% 
or more). ‡Values are based on 114 in the Exposed Group and 151 in the Not Exposed Group. ‡‡ Values are based on 98 in the Exposed Group 
and 95 in the Not Exposed Group. ¶Values are based on 101 in the Exposed group and 96 in the Not Exposed Group. ¶P Values are based on 98 
in the Exposed Group and 64 in the Not Exposed Group. † Values are based on 111 in the Exposed Group and 110 in the Not Exposed Group.
Table 4: Maternal outcomes for women receiving/not receiving antenatal corticosteroids with birth 24 to < 34 weeks gestational age
Antenatal corticosteroids
Received Not received Relative Risk 95% CI p-value
n = 104 n = 148
Induction of labour ‡ 3 (3) 11 (23) 0.14 0.04; 0.47 0.01
Primary postpartum haemorrhage (≥ 500 ml) ‡ 27 (26) 22 (15) 1.68 1.02; 2.79 0.04
Major haemorrhage (≥ 1000 ml) ‡ 8 (8) 7 (5) 1.57 0.58; 4.19 0.42
Postpartum pyrexia ≥ 38°C ‡ 9 (9) 2 (1) 6.53 1.44; 29.5 0.01
Figures are numbers with percentages rounded to the nearest whole number in brackets and with relative risk and 95% confidence intervals as the 
comparative statistic. ‡Outcomes not available for a few women.Page 4 of 8
(page number not for citation purposes)
BMC Pregnancy and Childbirth 2008, 8:47 http://www.biomedcentral.com/1471-2393/8/47Dexamethasone was the only antenatal corticosteroid
used across the nine hospitals. Repeat courses of antenatal
corticosteroids were given to 6% of women.
Maternal demographics (Table 2)
Overall, women who gave birth at less than 34 weeks ges-
tational age who received antenatal corticosteroids were
similar in age to women who did not receive antenatal
corticosteroids (mean maternal age 27.6 years (Standard
Deviation (SD) 6.8) and 28.5 years (SD 6.9) respectively).
Nearly all women in this audit attended a public hospital
throughout their pregnancy. Compared with women who
did not receive antenatal corticosteroids, women who did
were less likely to have had a previous pregnancy ≥ 22
weeks (RR 0.77, [95%CI 0.60, 0.99], p = 0.04), almost
three times as likely to have a multiple pregnancy (RR
2.84, [95%CI 1.0, 8.1], p = 0.04) and less likely to be
booked for birth at the hospital (RR 0.86, [95%CI 0.77,
0.96], p = 0.01). For women receiving antenatal corticos-
teroids, most had their last injection after 28 weeks gesta-
tion. Similar numbers of women received their last
injection between 28 to 31 weeks and between 32 to < 34
weeks gestation (40% and 40%).
There were significant differences in the distributions of
the main reason women were considered at risk of pre-
term birth between the mothers who were administered
corticosteroids and those who did not receive them (p =
0.01) (Table 2). More women who received antenatal cor-
ticosteroids were in preterm labour, or had preterm prela-
bour rupture of the membranes or hypertension.
Although health outcomes for the mother and their
infants are compared below by whether exposed or not to
antenatal corticosteroids, it needs to be remembered these
are not randomised groups. Groups may well differ by
other factors influencing health outcomes besides the
exposure or not to corticosteroids.
Infant health outcomes (Table 3)
Infants exposed to antenatal corticosteroids were born at
a similar gestational age and had similar birth weights to
infants who were not exposed. The majority of infants in
both groups were born between 28 to < 34 weeks (82%
and 80% respectively). Infants exposed to antenatal corti-
costeroids were less likely to be stillborn (RR 0.06,
[95%CI 0.02, 0.25], p = 0.01) and were less likely to die
prior to hospital discharge (stillbirth and death prior to
discharge combined, RR 0.49, [95%CI 0.30, 0.79], p =
0.01) compared with infants who were not exposed. Live
born infants who were not exposed were more likely to be
discharged alive than infants who were exposed to antena-
tal corticosteroids (RR 0.92, [95%CI 0.84, 1.0], p = 0.05].
The distribution of severity of any lung disease was signif-
icantly different in infants exposed to antenatal corticos-
teroids with fewer infants having respiratory problems
compared with infants who were not exposed (p = 0.01).
Low Apgar scores (< 7) at 1 minute and 5 minutes were
less likely for infants exposed to antenatal corticosteroids
compared with infants who were not exposed (RR 0.73,
[95%CI 0.54, 0.98], p = 0.04 and RR 0.44, [95%CI 0.25,
0.75], p = 0.01 respectively).
The risk of respiratory distress syndrome, use of mechani-
cal ventilation and use of oxygen therapy were not statis-
tically different between the two groups of infants.
Maternal health outcomes (Table 4)
Significantly fewer women who received antenatal corti-
costeroids were induced (RR 0.14, [95%CI 0.04, 0.47], p
= 0.01) however they were almost twice as likely to have a
caesarean section (RR 1.85, [95%CI 1.28, 2.67], p = 0.01)
compared with women not who did not receive antenatal
corticosteroids. A primary postpartum haemorrhage (≥
500 ml) was more likely for women who received antena-
tal corticosteroids (RR 1.68, [95%CI 1.02, 2.79], p = 0.04)
and they were over six times more likely to develop a post-
partum pyrexia (≥ 38°C) compared with women who did
not receive them (RR 6.53, [95%CI 1.44, 29.5], p = 0.01).
Discussion
An audit by the SEA-ORCHID group across four South
East Asian countries found the use of antenatal corticos-
teroids to be one of the least performed beneficial inter-
ventions in the prenatal period at collaborating hospitals
within those countries [9]. We therefore conducted this in
depth review of antenatal corticosteroid use prior to pre-
term birth in women presenting to the nine hospitals in
four South East Asian countries to compare sociodemo-
graphic factors, obstetric history and birth and infant out-
comes between women exposed and non-exposed.
This review reported varying uptake of these guidelines
into practice both between the nine hospitals in the four
South East Asian countries that were audited and between
the countries themselves. Within the countries, there was
no obvious relationship between the type of hospital and
the implementation of the use of corticosteroids, as use
varied between hospitals within some countries and was
similar between hospitals in other countries. These find-
ings highlight the need to examine the barriers and ena-
blers to adoption of the use of antenatal corticosteroids
among maternal and infant health practitioners at the
individual hospitals. Furthermore, it illustrates potential
benefit in each hospital developing its own locally rele-
vant clinical practice guideline for antenatal corticosteroid
administration so as to encourage standardised best prac-
tice.Page 5 of 8
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collaborating hospitals who received antenatal corticos-
teroids were more likely to be experiencing their first preg-
nancy and have a multiple pregnancy but were less likely
to be booked at the hospital for birth. There remains
doubt about the use of antenatal corticosteroids in multi-
ple pregnancies. One study has reported similar risks of
death or major morbidity between singleton and multiple
infants [11] while other studies suggest that antenatal cor-
ticosteroid therapy does not significantly reduce the inci-
dence of respiratory distress syndrome in multiple
gestations [12-15]. Further analysis of health outcomes of
infants from multiple pregnancies need to be analysed to
provide evidence either for or against this practice [4].
Our review showed that in the nine hospitals in the four
South East Asian countries audited, over 80% of corticos-
teroids administered were given when women were over
28 weeks gestation. Gestational age at which antenatal
corticosteroids should be given has long been a topic of
debate. An earlier systematic review showed limited evi-
dence of benefit if given at less than 28 weeks [16]
although the updated systematic review shows respiratory
distress syndrome is reduced when corticosteroids are
given in multiple doses with the first injection between 26
to 29.9 weeks [4].
The type of antenatal corticosteroid used between coun-
tries and between hospitals within countries did not dif-
fer, with dexamethasone the only corticosteroid used. It is
recognised that the frequency of respiratory distress syn-
drome is decreased by both betamethasone and dexame-
thasone [4], although there is still uncertainty concerning
which corticosteroid provides better health outcomes
[17].
The reason as to only dexamethasone being used in the
South East Asian countries audited is most likely due to
financial reasons, given that dexamethasone is the less
expensive of the two corticosteroids. As a result of this,
dexamethasone is often simply the only drug available in
these developing countries.
Limited use of repeat steroids was reported for all four
South East Asian countries. Evidence for the use of a single
course of antenatal corticosteroids for women at risk of
preterm birth has been acknowledged and accepted and it
has become recommended standard care [7,18,19]. At the
time of this audit, evidence regarding the effects of repeat
courses of antenatal corticosteroids was still unclear [20].
The published systematic reviews on antenatal corticoster-
oids papers [4] report positive health outcomes for moth-
ers and infants. The few negative health outcomes seen in
our audit are likely to reflect selection bias due to the use
of selective, non randomised groups.
Based on abundant evidence suggesting that antenatal
corticosteroids positively influence infant survival for pre-
term birth, and the audit result of varying uptake of this
intervention in the participating hospitals, it is obvious
that barriers to uptake of practice, in particular access to
evidence-based practice guidelines and recommendations
need to be examined at the individual institutions. As part
of the SEA-ORCHID project we plan to conduct a survey
of evidence-based practice knowledge and clinical change
among maternal and infant health practitioners in South-
East Asia to explore this issue.
A similar intervention undertaken in Thailand increased
the rate of use of antenatal corticosteroids for women who
gave birth preterm (< 34 weeks gestation) from a baseline
rate of 41% to 73% after evidence became available and
was disseminated [21]. Prior to this intervention an
increase from 33% to 58% for the rate of antenatal corti-
costeroid administration in the US was achieved after dis-
tribution of information. A further increase to 68% was
achieved after further knowledge of evidence distribution
[22].
Conclusion
This audit across four South East Asian countries indicates
that rates of use of antenatal corticosteroids are varied in
the hospitals participating in the SEA-ORCHID project.
Antenatal corticosteroids given to women prior to preterm
birth had significant health benefits for their babies. The
findings of this review highlight an important gap in best
practice recommendations that could be improved with
relatively low cost and with great benefit to neonatal out-
comes in resource poor countries. Barriers to uptake and
implementation of evidence-based practice guidelines
need to be evaluated and addressed and form part of the
ongoing SEA-ORCHID project [8].
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